AI-generated content for informational purposes only. Not financial advice. Always do your own research.

حول

Global medical products company providing essential therapies for kidney disease, hospital care, and surgical procedures. Over 85 years of healthcare innovation.

أسهم الشيخوخة السكانية

Baxter توفر العلاجات الأساسية لأمراض الكلى والرعاية المستشفائية والإجراءات الجراحية، مع أكثر من 85 سنة من الابتكار في مجال الرعاية الصحية تخدم السكان المسنين.

Key Financials BAX

السعر $19.79
التغيير (1 يوم) +5.77%
التغيير (30D) +3.56%
التغيير (60D) +11.37%
التغيير (90D) -14.51%
التغيير (180D) -35.28%
التغيير (1Y) -34.66%
التغيير (5Y) -74.30%
P/E Ratio 4.95
EPS (TTM) $4.00
نطاق 52 أسبوعاً $17.40 — $37.74
50-Day MA $19.74
الحجم 15.81M

Data updated Feb 15 · Source: Twelve Data

3.4
1 reviews
Demographic Exposure
3.8
Regulatory Risk
3
Growth Potential
2.5
Dividend Reliability
2
Financial Stability
1.8
Claude Opus 4.6
AI Review
3.4/5

Baxter International, a major medical products and renal care company, presents a complex investment case. The stock has suffered a dramatic decline"down 74% over five years and 35% over the past year"reflecting significant operational challenges, debt concerns from the Hill-Rom acquisition, and the recent divestiture of its kidney care segment (Vantive). The remarkably low P/E of 4.95 with EPS of $4.00 suggests either deep value or earnings that may not be sustainable in their current form post-restructuring.

Bull case: Baxter's core hospital products and medication delivery businesses serve essential healthcare needs. The aging population thesis remains intact as elderly patients disproportionately consume hospital supplies, IV solutions, and infusion therapies. At under $20, much bad news appears priced in, and recent 30/60-day momentum suggests stabilization.

Bear case: Heavy debt load, ongoing restructuring risk, and the separation from its kidney care business removes a key aging-population growth driver. The 5-year destruction of shareholder value raises governance concerns. Trading near 52-week lows with the 180-day decline of 35% signals persistent institutional selling.

Baxter offers turnaround potential but carries substantial execution risk.

Demographic Exposure
3.8
Regulatory Risk
3
Growth Potential
2.5
Dividend Reliability
2
Financial Stability
1.8
Feb 15, 2026
Baxter International Screenshot

Added: Feb 15, 2026

baxter.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

كيفية اختبار استراتيجية التداول بأثر رجعي: الطرق والأخطاء الشائعة وما تعنيه النتائج فعلاً

كيفية اختبار استراتيجية التداول بأثر رجعي: الطرق والأخطاء الشائعة وما تعنيه النتائج فعلاً

كل متداول لديه استراتيجية تبدو رائعة في رأسه. الاختبار بأثر رجعي هو كيفية معرفتك ما إذا كانت تعمل فعلاً. إليك كيفية اختبار الاستراتيجيات بشكل صحيح والمقاييس التي تهم وسبب أن معظم نتائج الاختبار بأثر رجعي جيدة جداً لتكون حقيقية.